Fig. 5
From: IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia
High IL1RAP expression predicts poor survival and nonresponse to HSCT. Overall survival (A&C) and relapse-free survival (B&D) censored at HSCT (A&B) or post-HSCT (C&D) of intermediate-risk AML patients of the Leucegene cohort (n = 316, annotated according to the 2022 ELN classification) according to IL1RAP transcript levels determined by RNA sequencing